{
    "nct_id": "NCT04725994",
    "official_title": "An Open-Label, International, Multicenter, Phase 1b/2a Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX (Capecitabine and Oxaliplatin) or Irinotecan in Patients with Advanced Gastric Cancer",
    "inclusion_criteria": "* Group 1, patients with treatment-naïve recurrent or advanced metastatic gastric cancer including gastroesophageal junction or upper part of the stomach.\n* Group 2, patients with recurrent or advanced metastatic gastric cancer including gastroesophageal junction or upper part of the stomach, who were treated ≥2 times with palliative chemotherapy before screening.\n* At least 1 evaluable lesion for the dose escalation part and at least 1 measurable lesion according to RECIST v1.1 for the dose expansion part.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1.\n* Group 2 Part C, patients should have UGT1A1 genotype tested during or prior to screening.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic central nervous system or uncontrolled brain metastasis\n* Carcinomatous meningitis or its history.\n* For Group 1, patients who are HER 2 positive.\n* Any other concurrent uncontrolled illness including, but not limited to, active or ongoing symptomatic infection requiring IV antibiotic treatment, uncontrolled diabetes, hepatic, renal, or respiratory illness.\n* Severe or unstable angina, myocardial infarction or ischemia, symptomatic congestive heart failure, arterial or venous thromboembolism requiring coronary artery bypass graft or stent within the past 6 months or clinically significant cardiac dysrhythmia or New York Heart Association class II ~ IV heart disease within 6 months of randomization.\n* Uncontrolled hypertension\n* Immunocompromised patients, such as patients known to be serologically positive for HIV.\n* Patients with known active Hepatitis B or C infection.\n* Patients with known active or symptomatic pneumonitis, or history of non-infectious pneumonitis requiring steroids.\n* Diagnosis of a myelodysplastic syndrome/acute myeloid leukemia or its suspicious characteristics.\n* Any unresolved clinically significant Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 toxicity\n* Resting ECG with measurable QTcF &gt; 470 msec on 2 or more time points within a 24-hour period or family history of long QT syndrome.\n* Current use of a cytochrome P3A4 inhibitor or inducer and strong uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) inhibitors.",
    "miscellaneous_criteria": ""
}